Approved by the SITC Executive Committee June 2018, Updated April 2021The Society for Immunotherapy of Cancer (SITC) is committed to providing a safe, secure, collegial and welcoming environment for all participants and attendees at its in-person and virtual meetings and events, and to provide for equal opportunity and treatment of all participants and attendees, regardless of actual or perceived gender, gender identity, race, ethnicity, sexual orientation, ability, socioeconomic status, age or religion. All participants, including, but not limited to, attendees, speakers, volunteers, exhibitors, staff (including venue staff), exhibitors, contractors, vendors and other service providers, and anyone else present at SITC in-person or virtual meetings or events, are expected to abide by this policy. This policy applies to all SITC meeting-related events, including those sponsored by organizations other than SITC but held in conjunction with SITC events, in public or private facilities or on online platforms.
Photography, Social Media and Recording Policy
Photography, Screenshots and Recording
Program attendees at SITC in-person or virtual programs may use photographs, screenshots and audio/video recordings taken during oral or poster presentations provided that the photographs and recordings are strictly for personal, noncommercial use and are not to be published in any form, EXCEPT when the speakers or poster presenters explicitly state otherwise at the start of their presentations or by indicating so on their slides and posters through one of two mechanisms:
Virtual program attendees should not copy, take photographs, screenshots or videos of Q&A or any chat that takes place in the virtual space.
SITC encourages live tweeting and other social media during in person and virtual programs. Guidelines for the use of social media include:
Responsible Drinking: In-Person Programs
Both alcoholic and non-alcoholic beverages may be served at SITC networking and other events. SITC expects participants at its events to consume alcoholic beverages responsibly and comply with such rules, requirements and restrictions as SITC may establish in connection therewith. This may include rules, requirements and restrictions pertaining to the imposition of conditions (such as the requirement of providing identification) to obtain an alcoholic beverage, allowing SITC and other event staff to limit or deny service to any participant for any reason, and/or to require a participant to leave an event on account of failure to comply with applicable rules, requirements and restrictions.
Anti-Harassment and Other Misconduct
SITC in-person and virtual meetings and events are convened for purposes of professional development, to promote scholarly and educational interchange in the spirit of free inquiry and expression and to carry out SITC’s stated purposes and mission. Harassment of colleagues and other meeting or event participants undermines the principle of equity at the heart of SITC’s meetings and events and is inconsistent with the principles of free inquiry and free expression. Consequently, SITC considers such harassment to be a form of misconduct subject to appropriate remedial action as described herein.
All participants and attendees at SITC meetings and events are expected to abide by this anti-harassment policy in all meeting settings, virtual or in-person, as well as at any ancillary events and official and unofficial social gatherings.
Participants and attendees who witness potential harm to a meeting or event participant or attendee, are expected be proactive in helping mitigate or avoid that harm, to the extent practicable.
SITC reminds meeting and event participants and attendees that SITC has zero-tolerance for any form of harassment or discrimination at SITC in-person and virtual meetings and events. The Executive Directors (see contact information below) or any other SITC staff are available for consultation with any meeting or event participant or attendee who believes they have experienced any form of harassment while at any SITC meeting or event.
SITC reserves the right to take any action it deems necessary or appropriate, including immediate removal from or revocation of access to the meeting or event without warning or refund as well as imposition of further sanctions, in order to respond to any violation of this policy. Further, SITC reserves the right to prohibit anyone who violates this policy from attending any SITC future meeting or event.
Reporting Harassment or Unacceptable Behavior
Any participant or attendee who is subjected to or witnesses an incident of harassment or abusive behavior may be asked to file a written report. Reports should include identification of the offender (or description); behaviors or actions by that person; circumstances around the incident; day, time and session; and others present. All written reports will be kept confidential.
Threatening behaviors, harassment, intimidation or other unacceptable behaviors not reported during the meeting or event may be reported to SITC staff after the conference by contacting Mary Dean (see contact information below). All complaints will be treated seriously and responded to promptly.
A participant or attendee who believes he or she was falsely or unfairly accused of violating this policy should notify the Executive Director (see contact information below).
SITC Executive Director Contact Information:
Mary Dean, JD, CAEExecutive Director, SITC555 East Wells Street, Suite 1100Milwaukee WI 53202Phone: 414-918-3036E-mail: email@example.com
Personal Safety and Security: In-Person Programs
In addition to the foregoing, SITC works diligently to provide a safe and secure environment for all participants and attendees at its meetings and events. In this regard, SITC recommends the following precautions in connection with attendance at meetings and events:
If there is an emergency or if you need immediate assistance, you are encouraged to ask any SITC staff member, venue staff, on-site security personnel and/or the local police to help you.
PreambleThe Society for Immunotherapy of Cancer (SITC) is the world’s leading member-driven organization specifically dedicated to improving cancer patient outcomes by advancing the science and application of cancer immunotherapy. SITC is not-for-profit medical professional society of influential research scientists, physician scientists, clinicians, patients, patient advocates, government representatives and industry leaders dedicated to improving cancer patient outcomes by advancing the science and application of cancer immunotherapy. It is the mission of the Society for Immunotherapy of Cancer to improve cancer patient outcomes by advancing the science, development and application of cancer immunology and immunotherapy through our core values of interaction/integration, innovation, translation and leadership in the field.Policies/ProcessesThe affairs of the Society for Immunotherapy of Cancer (SITC) shall be conducted with concern for the avoidance of any real or apparent conflict of interest on the part of its investigators (PI, faculty, planners, and/or managers). Representatives of SITC should make known to the appropriate person (usually the president and or executive director) a conflict of interest that they might have on any matter under consideration by a group in which they participate. Those who have a conflict of interest on a matter, which comes to vote, shall not vote on any motion which involves the matter.
An actual conflict of interest arises when a person is in a position that requires the exercise of judgment on behalf of SITC and the person also has financial, professional or personal interests (either the person’s own or an interest that is attributed to the person by virtue of interests held by a spouse, partner, minor children or someone with whom income is directly shared) of the sort that is likely to, or does directly, interfere with the exercise of the individual’s judgment on behalf of SITC.
The appearance of a conflict of interest is present if there is a potential for the financial, professional or personal interests of a person (either the person’s own or an interest that is attributed to the person by virtue of interests held by a spouse, partner, minor children or someone with whom income is directly shared) to be at odds with the person’s obligation to SITC and the circumstances are such that a reasonable person with knowledge of the relevant facts would question the person's ability to act in SITC’s best interests and not be compromised by that person’s financial, professional or personal interests.
SITC representatives with a conflict may be leading experts on the subject matter under consideration, and SITC should have the benefit of their expertise. Therefore, members with a conflict of interest may be permitted to participate in consideration of a matter, but only after their conflict on that matter has been made known. It is not necessary that all details of the conflict be divulged to the rest of the group. However, it is necessary that all the discussants know enough so that they can receive the comments from the members with a conflict in their proper context. If it is determined that due to the conflict it is inappropriate for the member(s) to contribute to the conversation, the president or presiding officer, or committee chair persons will make that determination
Per NIH requirements, SITC complies with all requirements of 42 CFR 50, Subpart F, "Responsibility of Applicants for Promoting Objectivity in Research for which PHS Funding is Sought" (FCOI Regulation), as implemented in the 2011 Final Rule for grants and cooperative agreements.
SITC provides this Financial Conflicts of Interest (FCOI) policy to all investigators who affect the content of an educational activity and are required to disclose their own financial relationships; as well as relationships to products or devices their spouse/life partner have with commercial interests related to the content of the activity of any amount over the past 12 months.
SITC requires disclosure form completion from investigators, as a way to comply with NIH requirements and ensure they are informed of our policy, their disclosure responsibilities, and the federal regulation. Disclosure form completion is required: (1) No later than at the time of application for PHS-funded research; (2) At least annually during the period of the award; and (3) Within 30 days of discovering or acquiring a new significant financial interest (SFI).
The SITC President and/or Executive Director shall review disclosure forms, determine if relevant SFIs and FCOIs exist, and implement and monitor management plans for actual SFIs and FCOIs; these steps shall be guided by the SITC Board of Directors’ conflict disclosure guidelines.The Executive Director, along with the FCOI Assistant, shall send any required FCOI reports to NIH, according to the regulation. This includes but is not limited to annual reports, mitigation reports, and any findings of bias. Further, when requested, the Executive Director will promptly make information available to the NIH/HHS relating to any investigator disclosure of financial interests and SITC’s review of, and response to, such disclosure, whether or not the disclosure resulted in SITC’s determination of an FCOI.SITC National Office shall maintain all FCOI-related records that meet or exceed the regulatory requirements: For at least three (3) years from the date the final expenditures report is submitted to the PHS (NIH); and From other dates specified in 45 CFR 75.361, where applicable.Those in non-compliance with this policy and disclosure requirements may result in removal of an investigator from the relevant grant or project. After a determination of non-compliance, the SITC Executive Committee shall complete and document a retrospective review within 120 days. SITC does not apply for or receive grants for clinical research; as such, additional DHHS non-compliance reporting requirements do not apply.SITC shall meet all subrecipient FCOI requirements, as applicable.This policy is publicly posted on the SITC website. SITC will also publicly post any information concerningidentified FCOIs, in accordance with the regulation.
Additional Conflicts for Consideration
In addition to the above mentioned disclosure, the IRS requires disclosure if any of the organization’s officers, directors, trustees, or key employees, had a family relationship or business relationship with another of the organization’s officers, directors, trustees, or key employees, at any time during the organization’s tax year. For each family and business relationship, identify the persons and describe their relationship. It is sufficient to enter “family relationship” or “business relationship” without greater detail.
DefinitionsInvestigators are those:· defined as the PD/PI and any other person, regardless of title or position;· who are responsible for the design, conduct, or reporting of research funded by PHS, or proposed for suchfunding;· and may include, for example, collaborators or consultants.
Definition of Financial RelationshipFinancial relationships are those relationships in which the individual benefits by receiving a salary, royalty, intellectual property rights, consulting fee, honoraria for promotional speakers’ bureau, ownership interest (e.g., stocks, stock options or other ownership interest, excluding diversified mutual funds), or other financial benefit. Financial benefits are usually associated with roles such as employment, management position, independent contractor (including contracted research), consulting, speaking and teaching, membership on advisory committees or review panels, board membership, and other activities from which remuneration is received, or expected. ACCME considers relationships of the person involved in the CME activity to include financial relationships of a spouse or partner. Contracted research includes research funding where the institution gets the grant, manages the funds and the person is the principal or named investigator on the grant. There is no minimum dollar amount for relationships.
Definition of Commercial InterestA commercial interest is any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients. Providers of clinical service directly to patients are not commercial interests (unless the provider of clinical service is owned, or controlled by, a commercial interest).
Other Possible Financial Conflictso Paid consultancy or expert testimony within the past two yearso Research funding (identify subject matter and funding organization, if permissible)o Honoraria, stipends, or gifts exceeding $100 in value per engagement directly received from an entityo Royalties
Additionally, the 2011 revised regulation defines a “significant financial interest” as follows:(1) A financial interest consisting of one or more of the following interests of the Investigator (and those of theInvestigator’s spouse and dependent children) that reasonably appears to be related to the Investigator’sinstitutional responsibilities(i) With regard to any publicly traded entity, a significant financial interest exists if the value of anyremuneration received from the entity in the twelve months preceding the disclosure and thevalue of any equity interest in the entity as of the date of disclosure, when aggregated, exceeds$5,000. For purposes of this definition, remuneration includes salary and any payment forservices not otherwise identified as salary (e.g., consulting fees, honoraria, paid authorship);equity interest includes any stock, stock option, or other ownership interest, as determinedthrough reference to public prices or other reasonable measures of fair market value;
(ii) With regard to any non-publicly traded entity, a significant financial interest exists if the value of anyremuneration received from the entity in the twelve months preceding the disclosure, whenaggregated, exceeds $5,000, or when the Investigator (or the Investigator’s spouse or dependentchildren) holds any equity interest (e.g., stock, stock option, or other ownership interest); or
(iii) Intellectual property rights and interests (e.g., patents, copyrights), upon receipt of income related to such rights and interests.(2) Investigators also must disclose the occurrence of any reimbursed or sponsored travel (i.e., that which is paid on behalf of that individual and not reimbursed to the them so that the exact monetary value may not be readily available), related to their institutional responsibilities; provided, however, that this disclosure requirement does not apply to travel that is reimbursed or sponsored by a federal, state, or local government agency, an Institution of higher education as defined at 20 U.S.C. 1001(a), an academic teaching hospital, a medical center, or a research institute that is affiliated with an Institution of higher education. The Institution’s FCOI policy will specify the details of this disclosure, which will include, at a minimum, the purpose of the trip, the identity of the sponsor/organizer, the destination, and the duration. In accordance with the Institution’s FCOI policy, the institutional official(s) will determine if further information is needed, including a determination or disclosure of monetary value, in order to determine whether the travel constitutes an FCOI with the PHS-funded research.(3) The term significant financial interest does not include the following types of financial interests: salary, royalties, or other remuneration paid by the Institution to the investigator if they are currently employed or otherwise appointed by the Institution, including intellectual property rights assigned to the Institution and agreements to share in royalties related to such rights; any ownership interest in the Institution held by the Investigator, if the Institution is a commercial or for-profit organization; income from investment vehicles, such as mutual funds and retirement accounts, as long as the Investigator does not directly control the investment decisions made in these vehicles; income from seminars, lectures, or teaching engagements sponsored by a federal, state, or local government agency, an Institution of higher education as defined at 20 U.S.C. 1001(a), an academic teaching hospital, a medical center, or a research institute that is affiliated with an Institution of higher education; or income from service on advisory committees or review panels for a federal, state, or local government agency, an Institution of higher education as defined at 20 U.S.C. 1001(a), an academic teaching hospital, a medical center, or a research institute that is affiliated with an Institution of higher education.
SITC defines “business relationships” between two persons to include any of the following:
Ownership is measured by stock ownership (either voting power or value) of a corporation, profits or capital interest in a partnership or limited liability company, membership interest in a nonprofit organization, or beneficial interest in a trust. Ownership includes indirect ownership (for example, ownership in an entity that has ownership in the entity in question); there may be ownership through multiple tiers of entities.
Privileged relationship exception: A “business relationship” does not include a relationship between an attorney and client, a medical professional (including psychologist) and patient, or a priest/clergy and penitent/communicant.
END OF POLICY
Last updated: Aug. 3, 2018
Thank you for being part of our community. To ensure the best possible experience for all members, we have established some basic guidelines for participation.
By joining and using this community, you agree that you have read and will follow these rules and guidelines. You also agree to reserve discussions and shared files and content to that are best suited to the medium. This is a great medium with which to solicit the advice of your peers, benefit from their experience, and participate in an ongoing conversation. Questions should be directed to our Membership Department via the Contact Staff link on this site. Technical questions on association management issues should directed to our help desk via email at firstname.lastname@example.org.
Please take a moment to acquaint yourself with these important guidelines. If you have questions, contact the help desk. In order to preserve a climate that encourages both civil and fruitful dialogue, we reserve the right to suspend or terminate membership in this community for anyone who violate these rules.
Discussion Group Etiquette
The Legal Stuff
This site is provided as a service for the members of Society for Immunotherapy of Cancer. Society for Immunotherapy of Cancer is not responsible for the opinions and information posted on this site by others. We disclaim all warranties with regard to information posted on this site, whether posted by Society for Immunotherapy of Cancer or any third party; this disclaimer includes all implied warranties of merchantability and fitness. In no event shall Society for Immunotherapy of Cancer be liable for any special, indirect, or consequential damages or any damages whatsoever resulting from loss of use, data, or profits, arising out of or in connection with the use or performance of any information posted on this site.
Do not post any defamatory, abusive, profane, threatening, offensive, or illegal materials. Do not post any information or other material protected by copyright without the permission of the copyright owner. By posting material, the posting party warrants and represents that he or she owns the copyright with respect to such material or has received permission from the copyright owner. In addition, the posting party grants Society for Immunotherapy of Cancer and users of this site the nonexclusive right and license to display, copy, publish, distribute, transmit, print, and use such information or other material.
Messages should not be posted if they encourage or facilitate members to arrive at any agreement that either expressly or impliedly leads to price fixing, a boycott of another's business, or other conduct intended to illegally restrict free trade. Messages that encourage or facilitate an agreement about the following subjects are inappropriate: prices, discounts, or terms or conditions of sale; salaries; profits, profit margins, or cost data; market shares, sales territories, or markets; allocation of customers or territories; or selection, rejection, or termination of customers or suppliers.
Society for Immunotherapy of Cancer does not actively monitor the site for inappropriate postings and does not on its own undertake editorial control of postings. However, in the event that any inappropriate posting is brought to the attention of Society for Immunotherapy of Cancer we will take all appropriate action.
Society for Immunotherapy of Cancer reserves the right to terminate access to any user who does not abide by these guidelines.
Accessing the Web Site From Outside the United StatesThe Web Site is operated and maintained by us from the United States. If you access the Web Site from outside the United States, please be aware that any personal information from you will be transferred to, stored in, and processed in the United States.Third Party Web SitesTo the extent that the Web Site contains links to other, third-party web sites, we encourage you to take reasonable precautions when sharing your Personal Information on third party web sites. Please be aware that we have no control over the content and practices of such other sites and cannot accept responsibility for their respective privacy or use policies.Protecting Children
The Web Site is not intended for children under 16 years of age. We do not knowingly collect personally identifiable information from children under 16. If you are under 16, do not use or provide any information on the Web Site or provide any information about yourself to us, including your name, telephone number, email address or any screen name or user name you may use. If we learn we have collected or received personally identifiable information from a child under 16 without verification of parental consent, we will delete that information. If you believe we might have any information from or about a child under 16, please contact us at email@example.com or at the toll free telephone number set forth at the end of the this Privacy notice.Links to Other SitesThe Web Site may contain links to other websites. We are not responsible for the privacy practices or content of other websites. We encourage you to read the privacy statements and terms and conditions of each website that collects your personal information.Changes to This Notice
We reserve the right to revise, amend, or modify this Notice, the Web Site, our privacy and data security policies and our other policies and agreements at any time and in any manner. Notice of any revision, amendment, or modification will be posted in accordance with terms hereof. By continuing to use the Web Site, you agree to any changes in this Notice.Opt-Out RightsYou may opt out of receiving future communications from us and/or having your contact information displayed in our membership directory at any time by emailing an opt out request to firstname.lastname@example.org or calling us at the toll free number set forth at the end of this Notice. You may also be able to opt out of processes listed under “How We May Share Your Information” above. You may also request that we delete any personal information that we have collected from you, subject to exceptions as permitted by law. For further information regarding these and other rights you may have, please see our Rights and Responsibilities notice.
Rights and Responsibilities Under Applicable Privacy LawsWe recognize principles and requirements under applicable state, federal and foreign laws (including, without limitation, the General Data Protection Regulation (“GDPR”) adopted by the European Union, the California Consumer Privacy Act (“CCPA”), and the California Privacy Rights Act (“CPRA”) pertaining to privacy of information (collectively, “Privacy Directives”). Certain of the provisions set out below are addressed in previous sections of this Notice, but are nonetheless set forth below to the extent that they have particular application with respect to the requirements of applicable Privacy Directives.
We will undertake to comply with Privacy Directives with a view to ensuring that all information is:
Contact UsTo exercise your rights as described in this Notice, or to ask questions or make any comments about this Notice or our privacy practices, please contact us at email@example.com or Call 1-866-723-0678.
Our mailing address is:
We grant you permission to temporarily download one copy of the Web Site content, which we make available to Web Site users on the Web Site (the “Content”) for individual, non-commercial transitory viewing only. This is the grant of a license, not a transfer of title, and under this license you may not (a) modify or copy Content; (b) use the Web Site Content for any commercial purpose, or for any public display (commercial or non-commercial); (c) attempt to decompile or reverse engineer any software contained on the Web Site; (d) remove any copyright or other proprietary notations from the Content; or (e) transfer the Content to another person or "mirror" the Content on any other server.
The Web Site is our proprietary property and all Content, source code, databases, functionality, software, web site designs, audio, video, text, photographs, and/or graphics on the Web Site (collectively, the “Web Site Proprietary Components”), as well as the trademarks, service marks, and logos contained therein (the “Marks”), are owned or controlled by us or licensed to us, and are protected by copyright and trademark laws and various other intellectual property rights and unfair competition laws of the United States, foreign jurisdictions, and international conventions. Except as expressly provided in this Notice, no part of the Web Site and no Content or Marks may be copied, reproduced, aggregated, republished, uploaded, posted, publicly displayed, encoded, translated, transmitted, distributed, sold, licensed, or otherwise exploited for any commercial purpose whatsoever, without our express prior written permission.
This license shall automatically terminate if you violate any of these restrictions and may be terminated by us at any time. Upon terminating your viewing of these materials or upon the termination of this license, you must destroy any downloaded materials in your possession whether in electronic or printed format.
The Web Site, the Content and the Marks are provided on an “AS IS” basis for your information and individual use only. We make no warranties, expressed or implied, and hereby disclaims and negates all other warranties including, without limitation, implied warranties or conditions of merchantability, fitness for a particular purpose, or non-infringement of intellectual property or other violation of rights.
Further, we do not warrant or make any representations concerning the accuracy, likely results, or reliability of the use of the Web Site, the Content or the Marks or otherwise relating to the content on any sites linked to the Web Site.
In no event shall we or our directors, officers, members, employees, agents, vendors or suppliers be liable for any damages (including, without limitation, damages for loss of data or profit, or due to business interruption) arising out of the use or inability to use the Web Site, the Content or any services provided by us, even if we or our authorized representatives have been notified orally or in writing of the possibility of such damage. Because some jurisdictions do not allow limitations on implied warranties, or limitations of liability for consequential or incidental damages, these limitations may not apply to you.
The Web Site and/or Content and any other materials appearing on the Web Site could include technical, typographical, photographic or other errors. We do not warrant that the Web Site, the Content or any other materials on the Web Site are accurate, complete or current. We may make changes to the materials contained on the Web Site at any time without notice. However, we do not make any commitment to update the Web Site, the Content or any such materials.
We cannot guarantee the Web Site and/or the services we provide will be available at all times. We may experience hardware, software, or other problems or need to perform maintenance related to the Web Site and/or services, resulting in interruptions, delays, or errors. We reserve the right to change, revise, update, suspend, discontinue, or otherwise modify the web site at any time or for any reason without notice to you. You agree that we have no liability whatsoever for any loss, damage, or inconvenience caused by your inability to access or use the Web Site during any downtime or discontinuance of the Web Site. Nothing in this Notice will be construed to obligate us to maintain and support the Web Site or to supply any corrections, updates, or releases in connection therewith.
Visiting the Web Site, sending us emails, and completing online forms constitute electronic communications. You consent to receive electronic communications, and you agree that all agreements, notices, disclosures, and other communications we provide to you electronically, via email and on the Site, satisfy any legal requirement that such communication be in writing. YOU HEREBY AGREE TO THE USE OF ELECTRONIC SIGNATURES, CONTRACTS, ORDERS, AND OTHER RECORDS, AND TO ELECTRONIC DELIVERY OF NOTICES, POLICIES, AND RECORDS OF TRANSACTIONS INITIATED OR COMPLETED BY US OR VIA THE SITE. You hereby waive any rights or requirements under any statutes, regulations, rules, ordinances, or other laws in any jurisdiction which require an original signature or delivery or retention of non-electronic records, or to payments or the granting of credits by any means other than electronic means.
As stated above, we may, from time to time, change this Notice. We encourage you to visit and review this Notice frequently to stay informed. Other changes, including amendments made to the Notice to comply with legal requirements, will become effective immediately upon their initial posting.
By accessing and using the Web Site, you agree to defend, indemnify, and hold us harmless, including our affiliates, and all of our respective directors officers, members, agents, contractors, partners, and employees, from and against any loss, damage, liability, claim, or demand, including reasonable attorneys’ fees and expenses, due to or arising out of: (a) your use of the Web Site, the Content or any of our services, whether within the Web Site or otherwise; (b) breach of the terms of this Notice; (c) your violation of the rights of any third party, including but not limited to intellectual property rights; or (d) any harmful act toward us or any other user of the Web Site. Notwithstanding the foregoing, we reserve the right, at your expense, to assume the exclusive defense and control of any matter for which you are required to indemnify us, and you agree to cooperate, at your expense, with our defense of such claims. We will use reasonable efforts to notify you of any such claim, action, or proceeding which is subject to this indemnification upon becoming aware of it.
This Notice is governed by and shall be construed in accordance with the laws of the state of Wisconsin and you irrevocably submit to the exclusive jurisdiction of the courts in Wisconsin having jurisdiction over our principal office in Milwaukee, Wisconsin.
Tel: +1 414 271 2456 | Fax: +1 414 276 3349 | Email: firstname.lastname@example.org